((“ovarian cancer” OR “endometrial cancer” OR “cervical cancer” OR “gynecologic cancer”) AND (“PD-1” OR “PD-L1” OR “immune checkpoint inhibitor” OR pembrolizumab OR nivolumab OR durvalumab OR dostarlimab) AND (“PARP inhibitor” OR olaparib OR niraparib OR rucaparib OR talazoparib OR veliparib)). Here, PDCD1 is linked to cervical cancer.